Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The rational alternative for AIDS

The rational alternative for AIDS

By Steve Usdin Contributing Editor

By Steve Usdin

Contributing Editor

WASHINGTON - The race to develop HIV protease inhibitors is shaping up as a demonstration of the promise of rational drug design. Agouron Pharmaceuticals Inc. and Vertex Pharmaceuticals Inc. are emerging with products that could counter the immense manufacturing problems confronting pharmaceutical companies who will be first to market with the drugs.

Both biotech companies say their anti-AIDS protease inhibitors are simpler to manufacture and require lower doses than those under development by Merck, Roche and Abbott.

The relative ease of manufacturing and resulting lower costs, combined with competitive efficacies, could help AGPH and VRTX penetrate the market after the early protease inhibitors demonstrate the drug class’s benefits.

At last week’s meeting of the National AIDS Drug Development Task Force,

Read the full 1406 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers